Meeting objectives and introduction
David Maloney & Frederick Locke

Welcome to the solid tumors day
Kedar Kirtane & Allison Betof

 Session 1: CARs targeting cell surface proteins (part I)
Chairs: Saul Priceman & Jennifer Specht

• Targeting DTP cells to advance CAR T-cell therapy for solid tumors – NSCLC as a model: Elliott Brea
• LYL273 for refractory metastatic colorectal cancer: Benjamin Schlecter
• Optimizing GPC3 CAR T cells for relapsed/refractory solid tumors: David Steffin
• Intracerebroventricular dual-targeting CAR T cells for glioblastoma: are we on the right path?: Stephen Bagley
• Talk title TBC: Jennifer Specht

Panel discussion

Keynote talk 1
Talk title TBC: John Haanen

Break

Session 2: CARs targeting cell surface proteins (part II)
Chairs: Eric Smith & TBC                                                                   

• Training T cells for the harsh new world (of solid tumors): Saul Priceman
• GD2 CAR T cell therapy for H3K27-altered diffuse midline gliomas: Jasia Mahdi
• B7H3 CAR-T cell therapy in recurrent platinum resistant epithelial ovarian cancer: Oliver Dorigo
• Talk title TBC: Roisin O’Cearbhaill
• Clinical experience with A2B694, a logic‑gated CAR T therapy to treat solid tumors expressing mesothelin: Jeffrey Ward

Panel discussion

Session 3: T-cell engagers and TCRs for solid tumors
Chairs: Allison Betof & TBC 

• Mechanisms of T-cell immunogenicity against public neoantigens: Smita Chandran
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC

Panel discussion

Lunch

Session 4: TILs for solid tumors
Chairs: Allison Betof & Benjamin Creelan  

• OBX-115 in advanced melanoma: Rodabe Amaria
• Enrichment strategies for TIL in NSCLC: Benjamin Creelan
• TIL sequence in melanoma: Is earlier the right answer?: Daniel Olson
• Talk title: Lilit Karapetyan

Panel discussion           

Session 5: Novel technologies in solid tumors
Chairs: TBC & TBC

• Engineered HSCs for solid tumors: Nathan Welty
• Talk title TBC: Eric Smith
• Cytokine receptor engineering to supercharge CAR T-cells: Sebastian Kobold
• Armored CARs in solid tumors: Renier Brentjens
• Utilizing ex vivo CAR T-cell therapy for gastric/GEJ cancers: Changsong Qi

Panel discussion

Break

Session 6: CARs for autoimmune rheumatic disorders
Chairs: David Porter & Jeremias Motte

• Autologous CD19-CAR T in SLE, SSc and IIM – data from the CASTLE-trial: Melanie Hagen
• Talk title TBC: TBC
• Talk title TBC: TBC

Panel discussion

Day 1 conclusions
Kedar Kirtane & Allison Betof

 

Welcome reception

Welcome to Day 2
Claire Roddie & Caron Jacobsen

Keynote talk 2
Targeting non-canonical tumor-specific antigens with engineered T cells: Patrick Hwu  

Session 7: CARs for neurological autoimmune diseases
Chairs: Claire Roddie & TBC

• Talk title TBC: Pere Barba
• Talk title TBC: TBC
• Treatment of autoimmune neuropathies with autologous CD19-targeted CAR T-cells: Jeremias Motte
• New frontiers, new challenges: CARs for neurological autoimmune diseases: Matthew Lunning
• Talk title TBC: Tuan Vu

Panel discussion

Break

Session 8: T-cell engagers and CARs in CLL
Chairs: Alexey Danilov & TBC

• Liso-cel in CLL/SLL: Tanya Siddiqi
• Novel T-cell engagers for CLL/NHL:AZD5492: Mazyar Shadman
• Mechanisms of resistance to CAR T-cell therapy in CLL: Michael Bishop
• The future of therapeutics in Richter’s transformation: CAR-T vs. bispecifics or small molecules: Alexey Danilov

Panel discussion

Session 9: T-cell engagers and CARs in ALL
Chairs: Noelle Frey & Pere Barba

• New generation of CD19-bispecifics in ALL: Ibrahim Aldoss
• Dual-antigen targeting trial in B-ALL: Nirav Shah
• Talk title TBC: Bijal Shah

Panel discussion

Lunch

Session 10: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & TBC

• Talk title TBC: Stephen Strickland
• CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in relapsed/refractory AML and MDS: Maher Abdul-Hay
• Talk title TBC: TBC
• Advances with CAR T-cell therapy in pediatric AML: Swati Naik
• Novel CAR targets and strategies for the treatment of acute myeloid leukemia (AML): Tim Sauer

Panel discussion

Session 11: T-cell engagers in lymphoma
Chairs: Jason Westin & TBC

• The emerging role of mosunetuzumab as frontline therapy of follicular lymphoma: Lorenzo Falchi
• Epcoritamab: current data and ongoing trials in lymphoid malignancies: Alexey Danilov
• Talk title TBC: Jason Westin

Panel discussion

Break

Session 12: CARs in lymphoma
Chairs: Jeremy Abramson & Gloria Inés Iacoboni García-Calvo

• NK cell based cellular therapies for B-cell lymphoma: Paolo Strati
• CD5 CAR for T cell lymphoma: Marco Ruella
• JAK inhibition and CAR T-cell therapy: Michael Jain
• Talk title TBC: TBC

Panel discussion

Session 13: Dual-targeting CARs in lymphoma
Chairs: David Miklos & Marie José Kersten

• CD19/CD20 dual targeting CAR T in 2L+ DLBCL: Key data from Prizlo-cel (formerly JNJ-4496): Krish Patel
• Dual-antigen CAR T-cells with bicistronic design and rapid manufacturing with KITE 363/KITE 753 for lymphoma: Saurabh Dahiya
• Clinical results with Zamto-Cel, a dual CD20/CD19 CAR-T, in second- and third-line DLBCL: Nirav Shah
• Ronde-cel, a CD62L enriched CD19/CD20 CAR T-cell candidate, achieves robust expansion, high rates of durable complete response and retains a memory phenotype post-Infusion in patients with LBCL: Akil Merchant
• High CR rates with durable responses in high-risk MCL with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time (ATALANTA-1 MCL cohort): Marie José Kersten

Panel discussion

Day 2 conclusions
Caron Jacobsen

 

Faculty dinner

Welcome to Day 3
Frederick Locke

Keynote talk 3
The lymphoma microenvironment and resistance to CAR T-cell therapy: Michael Green

Session 14: Navigating the broader challenges in CAR T-cell therapy
Chairs: Sarah Nikiforow & Frederick Locke

• Talk title TBC (toxicities): Kai Rajeski
• Talk title TBC (relative cost vs BsABs): Krish Patel
• Talk title TBC (regulatory landscape): TBC
• Climbing the CAR T mountain in the community: Tara Graff

Panel discussion

Session 15: in vivo CARs in lymphoma and myeloma
Chairs: Saar Gill & TBC

• in vivo CAR T for hematologic malignancies: Saar Gill
• UB-VV111 for CD19+ B-cell malignancies: Michael Bishop
• Talk title TBC: TBC
• Talk title TBC: Kah Whye Peng
• Talk title TBC: TBC

Panel discussion

Break

Session 16: CARs for multiple myeloma
Chairs: Francesco Maura & Matthew Frigault

• Talk title TBC: TBC
• Cilta-cel updates from CARTITUDE 4 and beyond: Rakesh Popat
• Talk title TBC: Ciara Freeman
• CAR T-cell therapy as first line in newly diagnosed multiple myeloma patients: Juan Du
• Talk title TBC: Sham Mailankody

Panel discussion

Session 17: T-cell engagers for multiple myeloma
Chairs: Doris Hansen & Yi Lin

• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Sequential CAR T cell and bispecific antibody therapy for myeloma: Adam Cohen

Panel discussion

Meeting conclusions
Frederick Locke & David Maloney

Lunch and adjourn